The therapeutic potential of human multipotent mesenchymal stromal cells combined with pharmacologically active microcarriers transplanted in hemi-parkinsonian rats.
Identifieur interne : 000998 ( PubMed/Corpus ); précédent : 000997; suivant : 000999The therapeutic potential of human multipotent mesenchymal stromal cells combined with pharmacologically active microcarriers transplanted in hemi-parkinsonian rats.
Auteurs : Gaëtan J-R Delcroix ; Elisa Garbayo ; Laurence Sindji ; Olivier Thomas ; Claire Vanpouille-Box ; Paul C. Schiller ; Claudia N. Montero-MeneiSource :
- Biomaterials [ 1878-5905 ] ; 2011.
English descriptors
- KwdEn :
- Animals, Behavior, Animal, Cell Differentiation (drug effects), Female, Fluorescent Antibody Technique, Humans, Lactic Acid (chemistry), Laminin (chemistry), Mesenchymal Stem Cell Transplantation (methods), Microspheres, Multipotent Stem Cells (cytology), Neurotrophin 3 (chemistry), Neurotrophin 3 (pharmacology), Parkinson Disease (metabolism), Parkinson Disease (therapy), Polyglycolic Acid (chemistry), Rats, Rats, Sprague-Dawley, Stromal Cells (cytology), Tissue Engineering (methods).
- MESH :
- chemical , chemistry : Lactic Acid, Laminin, Neurotrophin 3, Polyglycolic Acid.
- cytology : Multipotent Stem Cells, Stromal Cells.
- drug effects : Cell Differentiation.
- metabolism : Parkinson Disease.
- methods : Mesenchymal Stem Cell Transplantation, Tissue Engineering.
- chemical , pharmacology : Neurotrophin 3.
- therapy : Parkinson Disease.
- Animals, Behavior, Animal, Female, Fluorescent Antibody Technique, Humans, Microspheres, Rats, Rats, Sprague-Dawley.
Abstract
Multipotent mesenchymal stromal cells (MSCs) raise great interest for brain cell therapy due to their ease of isolation from bone marrow, their immunomodulatory and tissue repair capacities, their ability to differentiate into neuronal-like cells and to secrete a variety of growth factors and chemokines. In this study, we assessed the effects of a subpopulation of human MSCs, the marrow-isolated adult multilineage inducible (MIAMI) cells, combined with pharmacologically active microcarriers (PAMs) in a rat model of Parkinson's disease (PD). PAMs are biodegradable and non-cytotoxic poly(lactic-co-glycolic acid) microspheres, coated by a biomimetic surface and releasing a therapeutic protein, which acts on the cells conveyed on their surface and on their microenvironment. In this study, PAMs were coated with laminin and designed to release neurotrophin 3 (NT3), which stimulate the neuronal-like differentiation of MIAMI cells and promote neuronal survival. After adhesion of dopaminergic-induced (DI)-MIAMI cells to PAMs in vitro, the complexes were grafted in the partially dopaminergic-deafferented striatum of rats which led to a strong reduction of the amphetamine-induced rotational behavior together with the protection/repair of the nigrostriatal pathway. These effects were correlated with the increased survival of DI-MIAMI cells that secreted a wide range of growth factors and chemokines. Moreover, the observed increased expression of tyrosine hydroxylase by cells transplanted with PAMs may contribute to this functional recovery.
DOI: 10.1016/j.biomaterials.2010.10.041
PubMed: 21074844
Links to Exploration step
pubmed:21074844Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The therapeutic potential of human multipotent mesenchymal stromal cells combined with pharmacologically active microcarriers transplanted in hemi-parkinsonian rats.</title><author><name sortKey="Delcroix, Gaetan J R" sort="Delcroix, Gaetan J R" uniqKey="Delcroix G" first="Gaëtan J-R" last="Delcroix">Gaëtan J-R Delcroix</name><affiliation><nlm:affiliation>Inserm, U646, 10 rue André Boquel, Angers, F49100 France.</nlm:affiliation></affiliation></author><author><name sortKey="Garbayo, Elisa" sort="Garbayo, Elisa" uniqKey="Garbayo E" first="Elisa" last="Garbayo">Elisa Garbayo</name></author><author><name sortKey="Sindji, Laurence" sort="Sindji, Laurence" uniqKey="Sindji L" first="Laurence" last="Sindji">Laurence Sindji</name></author><author><name sortKey="Thomas, Olivier" sort="Thomas, Olivier" uniqKey="Thomas O" first="Olivier" last="Thomas">Olivier Thomas</name></author><author><name sortKey="Vanpouille Box, Claire" sort="Vanpouille Box, Claire" uniqKey="Vanpouille Box C" first="Claire" last="Vanpouille-Box">Claire Vanpouille-Box</name></author><author><name sortKey="Schiller, Paul C" sort="Schiller, Paul C" uniqKey="Schiller P" first="Paul C" last="Schiller">Paul C. Schiller</name></author><author><name sortKey="Montero Menei, Claudia N" sort="Montero Menei, Claudia N" uniqKey="Montero Menei C" first="Claudia N" last="Montero-Menei">Claudia N. Montero-Menei</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21074844</idno><idno type="pmid">21074844</idno><idno type="doi">10.1016/j.biomaterials.2010.10.041</idno><idno type="wicri:Area/PubMed/Corpus">000998</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000998</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The therapeutic potential of human multipotent mesenchymal stromal cells combined with pharmacologically active microcarriers transplanted in hemi-parkinsonian rats.</title><author><name sortKey="Delcroix, Gaetan J R" sort="Delcroix, Gaetan J R" uniqKey="Delcroix G" first="Gaëtan J-R" last="Delcroix">Gaëtan J-R Delcroix</name><affiliation><nlm:affiliation>Inserm, U646, 10 rue André Boquel, Angers, F49100 France.</nlm:affiliation></affiliation></author><author><name sortKey="Garbayo, Elisa" sort="Garbayo, Elisa" uniqKey="Garbayo E" first="Elisa" last="Garbayo">Elisa Garbayo</name></author><author><name sortKey="Sindji, Laurence" sort="Sindji, Laurence" uniqKey="Sindji L" first="Laurence" last="Sindji">Laurence Sindji</name></author><author><name sortKey="Thomas, Olivier" sort="Thomas, Olivier" uniqKey="Thomas O" first="Olivier" last="Thomas">Olivier Thomas</name></author><author><name sortKey="Vanpouille Box, Claire" sort="Vanpouille Box, Claire" uniqKey="Vanpouille Box C" first="Claire" last="Vanpouille-Box">Claire Vanpouille-Box</name></author><author><name sortKey="Schiller, Paul C" sort="Schiller, Paul C" uniqKey="Schiller P" first="Paul C" last="Schiller">Paul C. Schiller</name></author><author><name sortKey="Montero Menei, Claudia N" sort="Montero Menei, Claudia N" uniqKey="Montero Menei C" first="Claudia N" last="Montero-Menei">Claudia N. Montero-Menei</name></author></analytic><series><title level="j">Biomaterials</title><idno type="eISSN">1878-5905</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Behavior, Animal</term><term>Cell Differentiation (drug effects)</term><term>Female</term><term>Fluorescent Antibody Technique</term><term>Humans</term><term>Lactic Acid (chemistry)</term><term>Laminin (chemistry)</term><term>Mesenchymal Stem Cell Transplantation (methods)</term><term>Microspheres</term><term>Multipotent Stem Cells (cytology)</term><term>Neurotrophin 3 (chemistry)</term><term>Neurotrophin 3 (pharmacology)</term><term>Parkinson Disease (metabolism)</term><term>Parkinson Disease (therapy)</term><term>Polyglycolic Acid (chemistry)</term><term>Rats</term><term>Rats, Sprague-Dawley</term><term>Stromal Cells (cytology)</term><term>Tissue Engineering (methods)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Lactic Acid</term><term>Laminin</term><term>Neurotrophin 3</term><term>Polyglycolic Acid</term></keywords><keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Multipotent Stem Cells</term><term>Stromal Cells</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cell Differentiation</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Mesenchymal Stem Cell Transplantation</term><term>Tissue Engineering</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Neurotrophin 3</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Behavior, Animal</term><term>Female</term><term>Fluorescent Antibody Technique</term><term>Humans</term><term>Microspheres</term><term>Rats</term><term>Rats, Sprague-Dawley</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Multipotent mesenchymal stromal cells (MSCs) raise great interest for brain cell therapy due to their ease of isolation from bone marrow, their immunomodulatory and tissue repair capacities, their ability to differentiate into neuronal-like cells and to secrete a variety of growth factors and chemokines. In this study, we assessed the effects of a subpopulation of human MSCs, the marrow-isolated adult multilineage inducible (MIAMI) cells, combined with pharmacologically active microcarriers (PAMs) in a rat model of Parkinson's disease (PD). PAMs are biodegradable and non-cytotoxic poly(lactic-co-glycolic acid) microspheres, coated by a biomimetic surface and releasing a therapeutic protein, which acts on the cells conveyed on their surface and on their microenvironment. In this study, PAMs were coated with laminin and designed to release neurotrophin 3 (NT3), which stimulate the neuronal-like differentiation of MIAMI cells and promote neuronal survival. After adhesion of dopaminergic-induced (DI)-MIAMI cells to PAMs in vitro, the complexes were grafted in the partially dopaminergic-deafferented striatum of rats which led to a strong reduction of the amphetamine-induced rotational behavior together with the protection/repair of the nigrostriatal pathway. These effects were correlated with the increased survival of DI-MIAMI cells that secreted a wide range of growth factors and chemokines. Moreover, the observed increased expression of tyrosine hydroxylase by cells transplanted with PAMs may contribute to this functional recovery.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21074844</PMID><DateCreated><Year>2010</Year><Month>12</Month><Day>24</Day></DateCreated><DateCompleted><Year>2011</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-5905</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Biomaterials</Title><ISOAbbreviation>Biomaterials</ISOAbbreviation></Journal><ArticleTitle>The therapeutic potential of human multipotent mesenchymal stromal cells combined with pharmacologically active microcarriers transplanted in hemi-parkinsonian rats.</ArticleTitle><Pagination><MedlinePgn>1560-73</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biomaterials.2010.10.041</ELocationID><Abstract><AbstractText>Multipotent mesenchymal stromal cells (MSCs) raise great interest for brain cell therapy due to their ease of isolation from bone marrow, their immunomodulatory and tissue repair capacities, their ability to differentiate into neuronal-like cells and to secrete a variety of growth factors and chemokines. In this study, we assessed the effects of a subpopulation of human MSCs, the marrow-isolated adult multilineage inducible (MIAMI) cells, combined with pharmacologically active microcarriers (PAMs) in a rat model of Parkinson's disease (PD). PAMs are biodegradable and non-cytotoxic poly(lactic-co-glycolic acid) microspheres, coated by a biomimetic surface and releasing a therapeutic protein, which acts on the cells conveyed on their surface and on their microenvironment. In this study, PAMs were coated with laminin and designed to release neurotrophin 3 (NT3), which stimulate the neuronal-like differentiation of MIAMI cells and promote neuronal survival. After adhesion of dopaminergic-induced (DI)-MIAMI cells to PAMs in vitro, the complexes were grafted in the partially dopaminergic-deafferented striatum of rats which led to a strong reduction of the amphetamine-induced rotational behavior together with the protection/repair of the nigrostriatal pathway. These effects were correlated with the increased survival of DI-MIAMI cells that secreted a wide range of growth factors and chemokines. Moreover, the observed increased expression of tyrosine hydroxylase by cells transplanted with PAMs may contribute to this functional recovery.</AbstractText><CopyrightInformation>2010 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Delcroix</LastName><ForeName>Gaëtan J-R</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Inserm, U646, 10 rue André Boquel, Angers, F49100 France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garbayo</LastName><ForeName>Elisa</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Sindji</LastName><ForeName>Laurence</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Vanpouille-Box</LastName><ForeName>Claire</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Schiller</LastName><ForeName>Paul C</ForeName><Initials>PC</Initials></Author><Author ValidYN="Y"><LastName>Montero-Menei</LastName><ForeName>Claudia N</ForeName><Initials>CN</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>11</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Biomaterials</MedlineTA><NlmUniqueID>8100316</NlmUniqueID><ISSNLinking>0142-9612</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007797">Laminin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020933">Neurotrophin 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C043435">polylactic acid-polyglycolic acid copolymer</NameOfSubstance></Chemical><Chemical><RegistryNumber>26009-03-0</RegistryNumber><NameOfSubstance UI="D011100">Polyglycolic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>33X04XA5AT</RegistryNumber><NameOfSubstance UI="D019344">Lactic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005455" MajorTopicYN="N">Fluorescent Antibody Technique</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019344" MajorTopicYN="N">Lactic Acid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007797" MajorTopicYN="N">Laminin</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045164" MajorTopicYN="N">Mesenchymal Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008863" MajorTopicYN="Y">Microspheres</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039902" MajorTopicYN="N">Multipotent Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020933" MajorTopicYN="N">Neurotrophin 3</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011100" MajorTopicYN="N">Polyglycolic Acid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017154" MajorTopicYN="N">Stromal Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023822" MajorTopicYN="N">Tissue Engineering</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>09</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21074844</ArticleId><ArticleId IdType="pii">S0142-9612(10)01348-7</ArticleId><ArticleId IdType="doi">10.1016/j.biomaterials.2010.10.041</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000998 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000998 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:21074844
|texte= The therapeutic potential of human multipotent mesenchymal stromal cells combined with pharmacologically active microcarriers transplanted in hemi-parkinsonian rats.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:21074844" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |